SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vaxart, Inc., a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced today it will present at Jefferies 2016 Healthcare Conference in New York City.
Wouter Latour, M.D., Chief Executive Officer, will give a presentation on Vaxart on Thursday, June 9, 2016 at 10:00 a.m., Eastern Standard Time. The presentation will cover Vaxart’s proprietary oral vaccine platform and latest developments on its tablet vaccines for respiratory syncytial virus (RSV), norovirus and seasonal influenza.
Vaxart is a clinical-stage company developing tablet vaccines based on its proprietary oral vaccine platform. The lead programs are oral vaccines for RSV, norovirus and seasonal influenza. Vaxart vaccines are administered using convenient room temperature-stable tablets that can be stored and shipped without refrigeration, are easy to administer, eliminate risk of needle-stick injury and medical waste associated with injectable vaccines. The company is backed by Care Capital, Finney Capital, Quantum Technology Partners, Life Science Angels, Sand Hill Angels and Bay Partners. For more information, please visit www.vaxart.com.